Fig. 8: Tebentafusp treatment promotes TAM reprogramming in a patient with mUM. | Nature Communications

Fig. 8: Tebentafusp treatment promotes TAM reprogramming in a patient with mUM.

From: Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer

Fig. 8

a Schematic illustration of tumor sample processing for single-cell RNA sequencing from a patient prior to, and 18 months on tebentafusp treatment. b UMAP plot showing the monocyte, dendritic cell, and macrophage clusters in tumors prior to, and 18 months on tebentafusp treatment. c Percentages of pre-treatment TAM and tebentafusp (Tebe)-induced TAM among the total identified TAM population (range 0-1). d UMAP plots showing the most expressed M1 and M2 genes. e Multivariate linear model analysis of M1 and M2 signatures across myeloid populations (* shows signatures that are significantly enriched or depleted in the indicated cell type). f Average expression of M1 and M2 associated genes in tebentafusp-induced and pre-treatment TAM subsets (p values are shown using a Wilcoxon rank sum test). g M1- and M2-associated gene expression profiles of pre-treatment TAM and tebentafusp-induced TAM populations (n = 1 patient). Abbreviations: M1 = M1 macrophages, M2 = M2 macrophages, Tebe = tebentafusp, TAM = Tumor-associated macrophages.

Back to article page